Since folks want to throw Cory under the bus...

[OneBlueDotBama]

59. Being listed on a provincial formulary has nothing to with safety.

It only means those who receive reimbursement for a drug from the province, those on welfare etc., would have to wait for approval. Since most Canadians purchase their meds with their own cash, or their private employer has a drug plan, the CADTH Common drug review has no effect whatsoever.

In summary, there is one safety review of drugs, very similar to the FDA.

There is a secondary review for drug efficiency, by the Common Drug Review for listing on provincial formulary or dug plan.

CADTH Common Drug Review (CDR)

Once Health Canada has approved a drug for use in Canada, the country’s public drug plans must decide if the drug will be eligible for public reimbursement. The CADTH Common Drug Review (CDR) plays an important role in their decision-making processes.

Through the CDR process, CADTH conducts thorough and objective evaluations of the clinical, economic, and patient evidence on drugs, and uses this evaluation to provide reimbursement recommendations and advice to Canada’s federal, provincial, and territorial public drug plans, with the exception of Quebec.

Reviews are undertaken for new drugs, as well as existing drugs approved for new indications. To shorten the time between Health Canada regulatory approval and a CADTH reimbursement recommendation, a CDR application may be made while a drug is still being reviewed by Health Canada; however, the CADTH drug reimbursement recommendation is not issued until Health Canada approves the drug for use in Canada.

https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr